Rosen Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made false and misleading statements or concealed material adverse facts regarding the potential of setrusumab and the true risks within its study protocols. Investors are encouraged to join the class action, with a lead plaintiff deadline of April 6, 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ...
Rosen Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made false and misleading statements or concealed material adverse facts regarding the potential of setrusumab and the true risks within its study protocols. Investors are encouraged to join the class action, with a lead plaintiff deadline of April 6, 2026.